Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2022
Zealand Pharma (NASDAQ: ZEAL) has announced a notification from Credit Suisse Group AG regarding a change in its shareholding. The major shareholder has reduced its stake to below the 5% threshold of Zealand's total share capital and voting rights. This change is in compliance with Section 38 of the Danish Capital Markets Act. Zealand, based in Copenhagen, focuses on developing innovative peptide-based medicines, with two products on the market and three in late-stage development.
- Two products currently on the market: V-Go® and Zegalogue®.
- Three additional drug candidates in late-stage development.
- Credit Suisse's holding falling below 5% could indicate reduced investor confidence.
Company announcement – No. 28 / 2022
Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2022
Copenhagen, DK and Boston, MA, 10 June 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders:
Credit Suisse Group AG has notified Zealand about a change of its total holding of shares and voting rights, in accordance with section 38 of the Capital Markets Act, and other financial instruments according to section 39(2)(1) of the Capital Markets Act and financial instruments with similar economic effect according to section 39(2)(2) of the Capital Markets Act, such that it now holds below the
Please see further details in the attached notification form.
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. Zealand markets V-Go®, a basal-bolus insulin delivery option for people with diabetes, and Zegalogue®, (dasiglucagon), the first and only glucagon analogue for the treatment severe hypoglycemia in pediatric and adult patients with diabetes aged 6 and above. License collaborations with Boehringer Ingelheim and AstraZeneca create opportunities for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development.
Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit http://www.zealandpharma.com.
Forward-Looking Statement
The above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.
For further information, please contact:
| Zealand Pharma Investor Relations |
| Claudia Styslinger |
| Argot Partners |
| investors@zealandpharma.com |
| Zealand Pharma Media Relations |
| David Rosen |
| Argot Partners |
| media@zealandpharma.com |
Attachment
FAQ
What major change occurred with Credit Suisse's shareholding in Zealand Pharma?
What is the stock symbol for Zealand Pharma?
What products does Zealand Pharma currently market?
What is the significance of Credit Suisse's stake reduction?
When was the shareholder announcement made?
